Back to Journals » Infection and Drug Resistance » Volume 2

Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus

Authors Peppard W, Daniels A, Fehrenbacher L, Winner J

Published 8 June 2009 Volume 2009:2 Pages 27—40


Review by Single anonymous peer review

Peer reviewer comments 3

William J Peppard1, Anne Daniels1, Lynne Fehrenbacher2, Jamie Winner3

1Froedtert Hospital Milwaukee, Wisconsin, USA; 2Aurora St Luke’s Medical Center Milwaukee, Wisconsin, USA; 3Clement J Zablocki VA Medical Center, Milwaukee, Wisconsin, USA

Abstract: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections have increased dramatically over the last two decades. The types of infections can range from complicated skin and skin structure infections (cSSSI) to pneumonia and endocarditis. Oral antimicrobial therapy, such as trimethoprim-sulfamethoxazole, clindamycin, long-acting tetracyclines, or linezolid may provide enhanced benefit to those with uncomplicated cutaneous lesions when used in conjunction with incision and drainage in an outpatient setting. However, resistance, susceptibilities, patient-specific circumstances, and adverse effects can impact a healthcare professional’s choice of antibiotics. In patients with complicated infections requiring hospitalization or parenteral treatment, vancomycin remains the drug of choice, even though increased resistance and decreased efficacy have crept into clinical practice. Linezolid, quinupristin/dalfopristin, daptomycin, and tigecycline are alternative intravenous agents for the treatment of CA-MRSA. Investigational agents such as dalbavancin, telavancin, oritivancin, iclaprim, ceftobiprole, ceftaroline, and others may expand our therapeutic armamentarium for the treatment of infections caused by CA-MRSA in the future.

Keywords: community-associated methicillin-resistant Staphylococcus aureus, CA-MRSA, complicated skin and skin structure infections, cSSSI, Panton-Valentine leukocidin, PVL, in vitro activity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.